Skip to main content

Table 3 Resistance of gedatolisib in SW620/GEDA could be reversed by Ko143 and verapamil

From: ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells

Drug IC50 ± SD
SW620/GEDA (μΜ)
Gedatolisib 5.323 ± 0.728
+ Verapamil (2 μM) 4.837 ± 0.521
+ Verapamil (5 μM) 2.433 ± 0.314*
+ Ko143 (2 μM) 1.442 ± 0.238*
+ Ko143 (5 μM) 0.713 ± 0.096*
Doxorubicin 0.353 ± 0.042
+ Verapamil (2 μM) 0.361 ± 0.037
+ Verapamil (5 μM) 0.174 ± 0.023*
Paclitaxel 0.767 ± 0.062
+ Verapamil (2 μM) 0.679 ± 0.065
+ Verapamil (5 μM) 0.411 ± 0.031*
Mitoxantrone 0.872 ± 0.076
+ Ko143 (2 μM) 0.341 ± 0.032*
+ Ko143 (5 μM) 0.172 ± 0.011*
Topotecan 2.517 ± 0.329
+ Ko143 (2 μM) 1.022 ± 0.016*
+ Ko143 (5 μM) 0.239 ± 0.036*
  1. *Presents when p value is < 0.05. Data was showed with mean ± SD, which is representative for at least three independent experiments